Latest Peplin news

news

13-feb-09

Form 10-Q quarterly report read more

Peplin Results for the Quarter Ended 31 December 2008 read more

09-Jan-09

Positive results for Peplin's Phase IIb AK Trial read more

16-Dec-08

Peplin completes enrolment for its first phase III AK clinical trial read more

02-Dec-08

Form 10-Q - Quarterly Report read more

Registration statement including financial report read more

API Manufacturing

Peplin owns and operates a GMP licensed, commercial-scale manufacturing facility located in Southport, Queensland, Australia for API production of our proprietary, lead compound PEP005 (ingenol mebutate), a well characterized and purified single molecular entity sourced from a rapidly growing plant called Euphorbia peplus. The entire production process involves cultivation, post-harvest processing, GMP extraction, purification and formulation of PEP005 using strict quality standards for use in clinical trials.

Various contractors based in southeast Queensland and internationally support these activities.